Ballad Health Reports FY20 Second Quarter Results

    NEXT STORY
    Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis
    PREV STORY
    ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Immune Design ...

    author_avatar
    NASDAQ Market News

    Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation

    External manufacturing agreement reached to enable production of clinical trial materials for SB204 and ...

    author_avatar
    NASDAQ Market News

    Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins

    STAMFORD, Conn., May 12, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical ...

    author_avatar
    NASDAQ Market News